Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

General Information and Reorganization Transaction - Additional Information (Details)

v3.25.2
General Information and Reorganization Transaction - Additional Information (Details) - USD ($)
 12 Months Ended
Jun. 07, 2024
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2023
Disclosure of reclassifications or changes in presentation [line items]        
Cash   $ 4,228,944 $ 3,589,244  
Current liabilities   673,207 168,849  
Net decrease in cash   639,700 (5,763,294) $ 9,330,782
Accumulated deficit   24,589,244 18,527,997  
Cash flows used in operating activities   $ (4,563,576) $ (6,247,016) (4,179,767)
Number of shares issued   4,341,956 2,573,903  
Net proceeds   $ 5,128,186 $ 234 $ 13,654,347
At-the-Market Offering        
Disclosure of reclassifications or changes in presentation [line items]        
Number of shares issued 391,017      
Average price of shares $ 1.9931      
Net proceeds $ 754,511      
Virax Biolabs Group Limited        
Disclosure of reclassifications or changes in presentation [line items]        
Date of incoporation   Sep. 02, 2021    
Virax Biolabs (UK) Limited        
Disclosure of reclassifications or changes in presentation [line items]        
Date of incoporation   Aug. 19, 2021    
Virax Biolabs HKCo Limited        
Disclosure of reclassifications or changes in presentation [line items]        
Date of incoporation   Apr. 14, 2020    
Virax Immune T- Cell Medical Device Company Limited        
Disclosure of reclassifications or changes in presentation [line items]        
Date of incoporation   Jan. 16, 2017    
Virax Biolabs Pte. Limited        
Disclosure of reclassifications or changes in presentation [line items]        
Date of incoporation   May 04, 2013    
Virax Biolabs Group Limited        
Disclosure of reclassifications or changes in presentation [line items]        
Percentage of capital owned   95.54%    
Third Party Shareholders        
Disclosure of reclassifications or changes in presentation [line items]        
Percentage of capital owned   4.46%    
Logico Bioproducts Corp.        
Disclosure of reclassifications or changes in presentation [line items]        
Date of incoporation   Jan. 21, 2011    
Shanghai Xitu Consulting Co., Limited        
Disclosure of reclassifications or changes in presentation [line items]        
Date of incoporation   Oct. 27, 2017    
Virax Biolabs USA Management, Inc.        
Disclosure of reclassifications or changes in presentation [line items]        
Date of incoporation   Aug. 01, 2022    
Virax Biolabs Group Holdings Ltd        
Disclosure of reclassifications or changes in presentation [line items]        
Date of incoporation   Feb. 22, 2023    
Virax Biolabs Trading B.V.        
Disclosure of reclassifications or changes in presentation [line items]        
Date of incoporation   Aug. 04, 2023    
Virax Biolabs UK Operating Limited        
Disclosure of reclassifications or changes in presentation [line items]        
Date of incoporation   Nov. 07, 2023